At Cellaria, we empower your research and data relevancy by sourcing and reprogramming Induced Pluripotent Stem cells (iPS) from a specific patient clinical profile.

Our pipeline is built to meet the customer’s project and assay-specific requirements for cellular characteristics and functionality. The scalability of our iPS cells range from one million to one billion cells and can be delivered on a predictable schedule. Ultimately, this results in a significant reduction in costs and time to delivery.

These tissue-specific cell models are used for a wide range of applications, including the study of biological pathways, drug screening and development, and investigating pharmacological and toxicological mechanisms of action. Cellaria’s innovative models expand the available platforms on which researchers can build the next generation of personalized therapies.

Download our Stem Cell Services Brochure

Why RNA Reprogramming?

Non-integrative RNA reprogramming has proven to be the most efficient and clinically-relevant method for the generation of human iPS cell lines from donor cells. The combination of this platform and our expertise ensures the delivery of high quality iPS cell lines to meet your specific needs.

Our Technical Edge

Cellaria’s stem cell program offers world-class expertise in the derivation, bioprocess scale-up, and differentiation of induced human pluripotent stem cells (iPSCs)  and leverages this to provide a single-source solution for your iPSC needs: patient sample sourcing, primary cell culture establishment, RNA reprogramming, iPSC line expansion/cell banking, bioprocess scale-up, characterization and differentiation.

• Patient-specific solutions
  Ability to source tissue and generate iPS cells from a specific patient clinical profile
• RNA reprogramming service offerings
  Integration-free, non-viral, safe and efficient
• Differentiation service offerings
  Readily available lineages offered at scale, coupled with flexible, efficient and iterative custom solutions
• Consultative science
  Industry-leading scientific experts will help to develop a cost-effective and milestone driven project to meet your research needs.
• Rigorous Quality Control Protocols
  Cellaria assures quality by understanding and defining the process by which we produce each cell type, and through frequent monitoring of cells in our QC testing protocols. Cells are delivered with a Certificate of Analysis that the researcher can use to reference the quality specifications set for each individual derivation and differentiation process. This includes but is not limited to assessing cell count, viability, genomic stability, and expression of lineage markers at the transcriptome and protein levels.
• Concierge customer and technical support
  Start-to-finish assistance and support throughout the entire process provided by a dedicated technical team.

Our Process

We can customize your project with Cellaria to include our full suite offering or specific services (listed below). Whatever the needs of your research team might be, we’re ready to collaborate with you.

Patient-Specific Tissue Sourcing (3-4 weeks)

Cellaria will work with you to source blood and tissue from clinically-relevant patient cohorts.  Our extensive network and experience in sample procurement allow us to identify and select the proper patient sample format to fit the specific clinical profile needed for your research program. We can source any tissue type and offer you the confidence of knowing that all tissue specimens are validated by a board-certified pathologist.

RNA Reprogramming (2-6 weeks)

Our team utilizes non-integrating RNA reprogramming technologies that allow for the generation of virus-free human iPSCs from human fibroblasts and endothelial progenitor cells—in as little as two weeks.

Induced Pluripotent Stem Cells (4 weeks)

iPSC colonies are screened and selected based on expression of pluripotent markers (e.g. Oct-4, Nanog, TRA-1), imaged and fully characterized using tri-lineage differentiation assays.

Expansion and Banking of Pluripotent Cells (8-12 weeks depending on project scope)

Cellaria delivers large-scale pluripotent cell production up to one billion cells in both 2D and 3D formats.

Our expansion and banking protocols incorporate xeno- and feeder-free cell culture substrates, culture, and cryopreservation media, to ensure consistent, high viability cell cultures upon thaw. Risk mitigation assays are available to assess the differentiation potential prior to full scale expansion and banking.

Cellular Differentiation Services

Cellaria has broad expertise in lineage-specific iPSC differentiation, allowing for the most flexible, adaptable, and customizable solutions for your project. Differentiated cells are fully characterized for lineage marker expression (RNA/Protein). Genomic and proteomic data generation and functional evaluation in vitro and in vivo are also available.

Current cell types offered include, but are not limited to:

• Neural Progenitor Cells (NPCs) 1-2 months
• Cortical, Dopaminergic, Motor Neurons 2-3 months
• Hepatocytes 1-2 months
• Cardiomyocytes 1-2 months
• Pancreatic Beta Cells

Additional services include karyotyping to assess genomic stability, qRT-PCR of pluripotency genes, or tri-lineage differentiation to assess in vitro pluripotential.

Cell-specific data packages can be generated both on transcriptomic and proteomic levels of analysis.